Camilo Ayala BretonNitwara WikanArinda AbbuhlDuncan R. SmithStephen J. RussellKah Whye PengMayo ClinicMahidol UniversityBuena Vista University2018-11-232018-11-232015-08-05Molecular Therapy - Oncolytics. Vol.2, (2015), 15012237277052-s2.0-85006158699https://repository.li.mahidol.ac.th/handle/123456789/35402© 2015 The American Society of Gene and Cell Therapy. The hybrid oncolytic vesicular stomatitis virus (VSV-FH) deleted for its G glycoprotein and displaying the measles virus (MV) envelope glycoproteins (hemagglutinin H and fusion F) is fusogenic, infects cells via any of the three MV receptors and has potent oncolytic activity against subcutaneous and disseminated myeloma tumors. To tailor VSV-FH as an oncolytic virus for ovarian cancer, we ablated its natural tropism and retargeted the virus by display of a single-chain antibody (scFv) with specificity to the HER-2/neu receptor. A panel of six VSVFH-αHER2 viruses displaying anti-HER2 scFv that bind to the same HER2 epitope but with different Kd(10-6to 10-11M, VSVFH-áHER2#6 to #11, respectively) were rescued and characterized. A Kdof at least 10.8 M is required for infection of HER-2 positive SKOV3ip.1 cells. The higher affinity viruses (10-8M) were able to infect and fuse SKOV3ip.1 cells more efficiently, inducing more extensive cytopathic effects. We next compared the antitumor potency of the viruses against SKOV3ip.1 tumor xenografts. In contrast to the saline-treated animals, one intratumoral injection of VSVFH-áHER2#9, #10, or #11 resulted in efficient tumor control. There was no significant difference between viruses with an affinity higher than 10.9 M in terms of oncolytic potency. VSVFH-áHER2 virus may be a promising agent for the treatment of HER-2 positive malignancies.Mahidol UniversityBiochemistry, Genetics and Molecular BiologyMedicineArticleSCOPUS10.1038/mto.2015.12